2013 Awards

Amgen Bursary

Comprehensive pharmacogenetic profiling of advanced colorectal cancer

Ayman Madi, Freeman Hospital, Newcastle upon Tyne and Cardiff University, UK

AstraZeneca Student Prize Award

The AstraZeneca Student Prize Award is awarded to one high-quality abstract submitted by a student. AstraZeneca is proud to support excellence in research by young scientists. The recipient receives a bursary covering registration, accommodation and travel to the NCRI Cancer Conference.

MicroRNA-135b promotes cancer progression acting as a downstream effector of oncogenic pathways in colon cancer

Nicola Valeri et al, Institute of Cancer Sciences, University of Glasgow, UK

British Association of Cancer Research (BACR)/Gordon Hamilton-Fairley Young Investigator Ward

The BACR/Gordon Hamilton-Fairley Young Investigator Award recognises and encourages the talents of junior cancer researchers.

Investigating the functional effects of FGFR2 mutations in endometrial cancer

Abbie Fearon et al, Barts Cancer Institute, London, UK

Children’s Cancer and Leukaemia Group (CCLG) McElwain Award

The CCLG McElwain Award will be offered for the best abstract on childhood cancer research. The award is in honour of Professor Timothy McElwain, one of the pioneers of cancer chemotherapy including childhood malignancies. The award is aimed at young scientists and clinicians who are in training or at early stages of their career.

RNA helicase A is essential for 1p36 gene KIF1Bb tumor suppression in neuroblastomas

Zhi Xiong Chen, Ludwig Institute for Cancer Research, Solna, Sweden and National University of Singapore

The Company of Biologists Travel Awards

The Company of Biologists recognises the importance and interest of the NCRI Cancer Conference for students and young post-docs travelling from countries outside of the EU. Recipients of the awards received a bursary of up to £800.00 to contribute to their travel expenses.

TLR2 and TLR4 polymorphisms, gene and protein expression in risk of sporadic colorectal cancer

Marcela Alcântara Proença, UNESP – São Paulo State University, São José do Rio Preto, Brazil

Proteasomal inhibition sensitizes cervical cancer cells to Mitomycin C induced bystander killing

Shivendra Vikram Singh, National Center for Cell Science, Pune, India

Mechanistic study of the interactions between Id1-overexpressing esophageal cancer cells and fibroblasts in the tumor microenvironment

Wen Wen Xu, University of Hong Kong

TBX3 plays a novel tumour suppressor role in fibrosarcomas where it activates COL1A2

Aretha Cooper, University of Cape Town, South Africa

Binding of anti-GRP78 autoantibodies to cell surface GRP78 promotes prostate cancer progression by activating tissue factor procoagulant activity

Ali Al-Hashimi, McMaster University, Hamilton, Canada

Gene resilencing following Decitabine therapy is initiated by nucleosome reoccupancy and is related to CpG island shore methylation

Vibha Patil, Lowy Cancer Centre, UNSW, Sydney, Australia

RNA helicase A is essential for 1p36 gene KIF1Bb tumor suppression in neuroblastomas

Zhi Xiong Chen, Ludwig Institute for Cancer Research, Solna, Sweden and National University of Singapore

European Association for Cancer Research Travel Awards

The EACR recognises the importance and interest of the NCRI Cancer Conference for delegates travelling from EU countries. Recipients of the awards received a bursary of up to €500.00 to contribute to their travel expenses.

Implication of the MACC1 promoter to restrict MACC1-induced metastasis

Manisha Juneja, Max Delbrück Center for Molecular Medicine, Berlin, Germany

The effect of cancer associated fibroblasts on invasion and proliferation of melanoma cells, in a 3D environment

Njainday Jobe, Charles University in Prague, Czech Republic

Characterisation of primary and relapsed mantle cell lymphoma genome using next generation sequencing platform

Chenglin Wu, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Inhibition of lymphoma vascularisation and dissemination via ligand-activated oestrogen receptor β

Muhammad Sharif Hasni, Karolinska Institute, Stockholm, Sweden

National Cancer Research Institute (NCRI) Prize Awards

The NCRI Prize Awards give basic and clinical researchers undertaking or within one year of graduation a prize bursary of up to £250 towards the cost of attending the Conference. Applicants for this award were asked why they chose to attend the NCRI Cancer Conference and their research and career will benefit by attending. The winners of the awards were selected on the basis of both the quality of their abstract and the strength of their supporting application.

The Hippo pathway polarises the actin cytoskeleton during collective migration of Drosophila border cells

Ichha Khanal et al, Cancer Research UK London Research Institute, UK

Pan-genomic analysis of hypoxic breast cancer reveals lncRNAs associated with clinicopathological features

Hani Choudhry et al, King Abdulaziz University, Jeddah, Saudi Arabia and The Wellcome Trust Centre for Human Genetics, University of Oxford, UK

First UK cohort of prostate stereotactic body radiotherapy (SBRT): Acute toxicity and early PSA outcomes

Alison Tree et al, The Royal Marsden NHS Foundation Trust, London, UK

MST2 dependent actin-microtubule interaction is required for tumour invasion and oncogene YAP activation in oral squamous cell cancer (oSCC)

Carles Escriu et al, Cancer Research UK Cambridge Institute, UK

Patients as authors

Christine Douglass et al, University of Westminster, London, UK

Tetraploidy is permissive for chromosomal instability and accelerates cancer genome evolution

Sally Dewhurst et al, Cancer Research UK, London Research Institute, UK

What determines the place of death for gynaecological cancer patients in England?

Sonali Kaushik et al, Cheltenham General Hospital, Gloucestershire, UK and South West Public Health Observatory, Bristol, UK

Hypoxia-responsive protein WSB-1 is regulated by HIF-1α and affects cellular motility

Flore-Anne Poujade et al, University of Hull, UK

TBX3 plays a novel tumour suppressor role in fibrosarcomas where it activates COL1A2

Aretha Cooper et al, University of Cape Town, South Africa

ICON8 trial stage IA analysis: Safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer (NCT 10356387, CRUK/10/030)

Jane Hook et al, Medical Research Council Clinical Trials Unit, London, UK and University College London Cancer Institute and University College London Hospitals, UK

Synergistic effect of the aurora kinase A (AK-A) inhibitor, MLN8237, in combination with paclitaxel in bladder cancer cells

Jennifer Harrington et al, University of Cambridge Cancer Research UK Cambridge Institute, UK

Mechanistic study of the interactions between Id1-overexpressing esophageal cancer cells and fibroblasts in the tumor microenvironment

Wen Wen Xu et al, University of Hong Kong

Investigating the underlying mechanisms of action of targeted radionuclide therapy in EGFR overexpressing solid tumours

Clara Chan et al, University of Manchester, UK

Implication of the MACC1 promoter to restrict MACC1-induced metastasis

Manisha Juneja et al, Max Delbrück Center for Molecular Medicine, Berlin, Germany

Stereotactic body radiation therapy (SBRT) for extracranial oligometastatic disease- can we change the therapeutic paradigm?

Katharine Aitken et al, Royal Marsden Hospital, London, UK

Identification and functional validation of miR-330 in regulating oesophageal adenocarcinoma sensitivity to chemotherapy

Becky Bibby et al, University of Hull, UK

Photoacoustic assessment of OXi4503 pharmacodynamic effect and tumour vessel regrowth in colorectal carcinoma xenograft models of cancer

Sean Peter Johnson et al, University College London Cancer Institute, UK

TLR2 and TLR4 polymorphisms, gene and protein expression in risk of sporadic colorectal cancer

Marcela Alcântara Proença et al, UNESP – São Paulo State University, São José do Rio Preto, Brazil

Developing quantitative assays for DNA double-strand break-induced mutations

Sara Ahrabi et al, Gray Institute for Radiation Oncology and Biology, Oxford, UK

Binding of anti-GRP78 autoantibodies to cell surface GRP78 promotes prostate cancer progression by activating tissue factor procoagulant activity

Ali Al-Hashimi et al, McMaster University, Hamilton, Canada

Royal College of Radiologists Ross Prizes

Endowed by Dr WM Ross, a past President of the College, these awards are presented to the clinical oncologists in training or recently appointed consultants adjudged to have presented the best proffered papers, posters or videos at a College meeting. The procedure for determining these awards was originally set by the Board of Faculty of Clinical Oncology.

Two prizes are awarded annually at the NCRI Cancer Conference: One for the best poster and one for the best proffered paper presentation. The winners were presented with a cheque for £200.00.

Best poster: Inhibition of ATM kinase preferentially abrogates glioblastoma cancer stem cell radioresistance

Ross Carruthers et al, University of Glasgow, UK

Best proffered paper: Increased blood flow to human rectal cancer induced by nelfinavir and radiotherapy

Esme Hill et al, University of Oxford and Churchill Hospital, Oxford, UK

No comments yet.

Leave a Reply